Pachydermoperiostosis (PDP) is a rare disorder of bone and connective tissue growth. A 21-year-old man was referred to our hospital with anemia. He showed characteristics of PDP. Bone marrow biopsy showed myelofibrosis. Chromosomal abnormalities or JAK2 mutation were not found. Anemia gradually progressed, and he became transfusion-dependent. Oral prednisolone was initiated; it gradually improved his anemia and rendered the patient free of transfusion. However, other clinical symptoms such as clubbed fingers and skin hypertrophy remained unimproved. In this case, the serum concentration of vascular endothelial growth factor and transforming growth factor-β levels were increased. Further investigation will be necessary to establish appropriate treatment strategies for this disease.
Introduction
Pachydermoperiostosis (PDP) is a rare primary hypertrophic osteoarthropathy appearing as a disorder of bone and connective tissue growth. The disease is characterized by the development of thickening of the fingers, cutis verticis gyrata, digital clubbing, oily skin, periosteal reactions, cortical thickening of the long bones and hypertrophic osteoarthropathy (1, 2) . In particular, the presence of digital clubbing, skin hypertrophy and radiographic periostosis are the main diagnostic criteria for PDP (3) . The disease is markedly more prevalent in males, and is thought to represent an autosomal dominant trait with variable expression. PDP symptoms also develop secondary to various acquired diseases, particularly intrathoracic neoplasms (4) . Cases of myelofibrosis in association with PDP are rare in the literature, and the pathogenesis of PDP has not been clarified. We report herein a case of myelofibrosis with PDP that was successfully treated using prednisolone (PSL).
Case Report
A 21-year-old man was referred to our hospital with anemia in August 2009. His birth had been uneventful and he grew up healthy. Facial wrinkles had become prominent in junior high school, with enlargement of the hands and feet evident from 17 years old. He observed that his fingers and toes gradually got thicker. College health checkups also noted facial abnormalities and anemia. On physical examination, the patient seemed older than his actual age. His height was 172 cm, and his weight was 65 kg. Cranial skin was thickened and corrugated, and deep nasolabial folds were apparent. He showed bilateral digital clubbing, and elephant feet (Fig. 1) . No joint pain was evident. Bone radiography showed hypertrophic osteoarthropathy and cortical thickening of the long bones (Fig. 2) . No cardiorespiratory or abdominal symptoms were present. Internal malignancy was not found on computed tomography, endoscopy or FDG-PET. Brain magnetic resonance imaging (MRI) re- vealed no abnormalities. Table 1 summarizes the laboratory findings at initial consultation. Leukocyte count was 3,950/ μL, hemoglobin level was 8.7 g/dL and platelet count was 11.5×10 4 /μL. The serum concentration of ferritin was elevated, but serum iron level was normal. Levels of growth hormone and thyroid hormone were normal, ruling out acromegaly and thyroid acropathy. No familial history of any similar disorder was evident. Bone marrow aspiration yielded dry taps and bone marrow biopsy showed hypocellularity with fibrosis ( Fig. 3A, 3B) . No hepatomegaly or splenomegaly was present. Chromosomal analysis showed 46,XY, with no JAK2 mutation. The diagnosis was myelofibrosis complicated with PDP.
Treatment with danazol had been initiated at another hospital, but proved ineffective. He was not receiving any therapy on presentation to our hospital, and anemia had gradually progressed to the point where the patient became transfusion-dependent. Oral administration of PSL was started at 30 mg/day in November 2009, resulting in a gradual improvement in anemia. The patient was able to become free of transfusion after PSL treatment (Fig. 4) . In September 2010, bone marrow biopsy showed the recovery of he- matopoiesis efficacy and improvement of fibrosis (Fig. 3C) . However, other clinical symptoms such as clubbed fingers and skin hypertrophy remained unimproved.
Discussion
This patient displayed the characteristic features of PDP, such as digital clubbing and radiographic periostosis. In this Prednisolone case, anemia was attributable to myelofibrosis. PDP complicated by myelofibrosis has been reported in only a few cases (5-7). Myelofibrosis is one of the primary forms of chronic myeloproliferative disorder, characterized by erythroblastic anemia, hepatosplenomegaly from extramedullary hematopoiesis, and dysplastic megakaryocytic hyperplasia associated with bone marrow fibrosis. The JAK2 V617F mutation is present in more than 90% of patients with polycythemia vera and in 40-60% of patients with idiopathic myelofibrosis (8) . In this case, the bone marrow was hypocellular with a decreased number of megakaryocytes, and no JAK2 mutation or chromosomal abnormalities were found. High levels of circulating CD34+ cells and JAK2 mutations might allow differentiation of myelofibrosis with myeloid metaplasia from other myeloproliferative disorders, including secondary myelofibrosis (9) . However, the JAK2 V617F mutation has been detected in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis (10) . In any case, the JAK2V617F mutation was not evident in this patient, so myelofibrosis in this case might have been secondary to PDP.
Cytokines such as vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β, hepatocyte growth factor, and platelet-derived growth factor are suspected to influence the pathogenesis of PDP and myelofibrosis (11) . Modifications to vessels in PDP are reportedly associated with diffuse endothelial hyperplasia showing activated endothelial cells, thickening of the basal membrane, and sclerosis with packing of collagen fibers (12) . In the present case, levels of VEGF and TGF-β were increased to 641 pg/mL (normal, <38.3 pg/mL); and 13.6 ng/mL (normal, 0.89-1.80 ng/mL), respectively. For patients with primary myelofibrosis, anabolic steroids are used as a treatment for anemia (13) . Indeed, the present patient was initially treated using danazol, although the treatment proved ineffective. In juvenile osteopetrosis, effective treatment of anemia or skeletal complications using PSL has been reported (14, 15) . In another case report, typical doses of PSL were not effective, and steroid pulse therapy improved anemia caused by myelofibrosis with PDP (5). In the present case, we selected PSL (0.5 mg/kg/day) as treatment in our hospital. This dose of PSL proved effective against anemia in the present case, and the patient was able to discontinue transfusions. Bone marrow biopsy showed improvement of fibrosis. However, serum concentrations of VEGF and TGF-β were not decreased. This result might suggest that these cytokines were not essential for myelofibrosis and another cytokine caused myelofibrosis in this case, indicating the complexity of the mechanisms underlying PDP. Indeed, other symptoms such as clubbed fingers or skin hypertrophy remained unimproved with oral administration of PSL. Myelofibrosis might be one of the important complications among patients with PDF. Adequate treatment strategies need to be established for PDP, and further investigation of the mechanisms underlying PDP with myelofibrosis are necessary.
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